FDA approves all ages gene therapy for spinal condition
Ella Jeffries / beckershospitalreview - The FDA approved Novartis’ Itvisma (onasemnogene abeparvovec-brve), the company’s first and only gene replacement therapy for spinal muscular atrophy in children 2 and older, as well as for teens and adults. The therapy is designed to address the genetic …
AI Summary: The FDA has given the green light to Novartis’ gene replacement therapy Itvisma for the treatment of spinal muscular atrophy, a development that extends its use to patients of all ages. The approval, which responds to long‐standing concerns over safety and patient eligibility, marks a significant milestone in SMA care.
Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61
Related Stories
Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128
FDA Lifts Hold on Intellia’s Phase 3 Gene Editing Trial / 4 months
FDA rejects Corcept’s cortisol modulator triggering setback / 4 months
FDA approves Rucaparib for advanced prostate cancer / 5 months
FDA approves first gene therapy for Wiskott‐Aldrich syndrome / 5 months
FDA Approves Ziftomenib for AML Treatment / 6 months
FDA updates Sarepta gene therapy label with severe warnings / 6 months
FDA clears AstraZeneca’s new blood-pressure drug baxdrostat / 13 days
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Research Funding, Oncology, Reproductive Health, Trump Administration and look for the RSS link.
StackHealth Time Machine